About Krebs Biochemicals & Industries Limited

Krebs Biochemicals & Industries Limited (CIN: L24110AP1991PLC103912) was incorporated on December 2, 1991, and is engaged in the manufacture of active pharmaceutical ingredients (APIs). The Company operates two multi-purpose manufacturing facilities in Andhra Pradesh:

• Unit I – Regadichelika, Kodavalur Mandal, Nellore District
• Unit II – Kothapalli, Kasimkota Mandal, Anakapalli (Visakhapatnam District)

Krebs Biochemicals’ operations include product sales, contract manufacturing/job work, and lease arrangements, as reflected in its revenue mix and related-party transactions with Ipca Laboratories Limited.

The Company reports a single business segment (Pharma) and does not present a separate geographical segment. Its manufacturing operations are based in India, with domestic and export revenues recognised on standard dispatch and shipping terms (domestic on Forwarding Note/lorry receipt and exports on Bill of Lading).

As of March 31, 2025, the Company’s shares were listed and actively traded on:

• BSE: 524518
• NSE: KREBSBIO
• ISIN: INE268B01013
  Dematerialisation level: 98.36%

Ipca Laboratories Limited held 49.65% of the Company’s equity as of March 31, 2025, along with promoter group holdings as disclosed in the Annual Report. The Company has no subsidiaries, associates, or joint ventures.

Krebs Biochemicals completed its 33rd Annual Report, underscoring over three decades of presence as an Indian API manufacturer since its incorporation in 1991.

Krebs Biochemicals & Industries Limited Key Management

• Dr. R. T. Ravi – Chairman, Non-Executive Director
• Mr. Manish Kumar Jain – Managing Director & CEO (with effect from August 7, 2025)
• Mr. Jitendra Shah – Managing Director & CEO (up to August 7, 2025)
• Mr. P. K. Bhattacharyya – Non-Executive Director
• Mr. Avinash Ravi – Non-Executive Director
• Mr. P. M. Kathariya – Independent Director (appointed February 4, 2025)
• Ms. Dipti Shah – Independent Director (appointed February 4, 2025)
• Mr. Satya Prakash Chigurupati – Independent Director (appointed February 4, 2025)
• Mr. Sumanth Karlapudi – Independent Director (appointed February 4, 2025)
• Mr. Ritesh Jain – Chief Financial Officer
• Mr. Rakesh R. Kalbate – Company Secretary & Compliance Officer

Latest Updates on Krebs Biochemicals & Industries Limited

Manufacturing status:
The Company’s Vizag (Unit II) operations have been closed since February 9, 2025, following an order issued by the Andhra Pradesh Pollution Control Board (APPCB). The Company is actively pursuing revocation of the closure order and plans to resume operations upon approval.
The Nellore facility (Unit I) continues to manufacture and sell APIs and has largely stabilised operations. Krebs is also exploring manufacturing partnerships for fermentation-based products to better utilise capacity.

Board composition and governance:
On February 4, 2025, the Board appointed four new Independent Directors — Mr. P. M. Kathariya, Ms. Dipti Shah, Mr. Satya Prakash Chigurupati, and Mr. Sumanth Karlapudi — for a term of five years. Shareholders approved the appointments on May 28, 2025 via postal ballot.
Earlier, BSE and NSE levied fines of Rs 5,000 per day for 33 days (Jan 1–Feb 3, 2025) for non-compliance under SEBI (LODR) Regulation 17(1) concerning Board composition; compliance was restored following these appointments.

Leadership transition:
Mr. Manish Kumar Jain assumed charge as Managing Director & CEO effective August 7, 2025, succeeding Mr. Jitendra Shah, who held the position until that date.

Auditor matters:

The Statutory Auditors flagged a material uncertainty regarding going concern, citing continued losses and negative net worth. Management stated that financial support from the principal promoter (Ipca Laboratories Limited) would be available if required, mitigating the concern.

Internal audit:
The Board re-appointed M/s. Suryanarayana & Suresh, Chartered Accountants, as Internal Auditors for FY 2025-26 on May 20, 2025. Quarterly audit reports were presented to the Audit Committee and Board for review.

Related-party framework:
The Company has sought shareholder approval to enter into material related-party transactions with Ipca Laboratories Limited for purchase/supply of materials and contract manufacturing/loan licence services for FY 2025-26, FY 2026-27, and beyond, all at arm’s-length and in the ordinary course of business.